A phase III clinical study of HFT-290.
Phase 3
- Conditions
- Cancer pain
- Registration Number
- JPRN-jRCT2080223308
- Lead Sponsor
- Hisamitsu Pharmaceutical Co.,Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients with a diagnosis of cancer who are informed about their disease.
Exclusion Criteria
- Patients with abnormalities at the target application site.
- Patients with serious cardiac, hepatic, or renal dysfunction, serious respiratory disease, or serious respiratory depression.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy, and safety.
- Secondary Outcome Measures
Name Time Method